<?xml version="1.0" encoding="UTF-8"?>
<p>The risks of respiratory tract sampling and additional blood tests being taken are minimal and where occurring are likely to be mild. No additional adverse events related to POCT for respiratory viruses are anticipated. However, active monitoring and reporting of severe adverse events will be undertaken. A serious adverse event (SAE) is any adverse event that:</p>
